ArticleInternational journal of clinical and experimental pathology2014
Role of high expression of IL-9 in prognosis of CLL.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Article
- The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023Review
- Upregulated Expression of the IL-9 Receptor on TRAF3-Deficient B Lymphocytes Confers Ig Isotype Switching Responsiveness to IL-9 in the Presence of Antigen Receptor Engagement and IL-4.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia.Journal of clinical medicine · 2023Review
- Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.Cancers · 2022Review
- Interleukin (IL)-9 Supports the Tumor-Promoting Environment of Chronic Lymphocytic Leukemia.Cancers · 2021Review
- Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.Cancers · 2021Review
- Expression and clinical significance of interleukin-9 in renal tumors.Translational andrology and urology · 2020Article
- The Role of Interleukin-9 in Cancer.Pathology oncology research : POR · 2020Review
- IL-9 and IL-9-producing cells in tumor immunity.Cell communication and signaling : CCS · 2020Review
- Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role.Cancers · 2020Review
- Th9 Cell Differentiation and Its Dual Effects in Tumor Development.Frontiers in immunology · 2020Review
- STAT6 phosphorylation upregulates microRNA-155 expression and subsequently enhances the pathogenesis of chronic lymphocytic leukemia.Oncology letters · 2019Article
- Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.Journal of experimental & clinical cancer research : CR · 2016Article
- Serum IL-9, IL-17, and TGF-β levels in subjects with diabetic kidney disease (CURES-134).Cytokine · 2015Article
- Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia (CLL) is a common leukemia in adults, but its pathogenesis is still poorly understood. Interleukin-9 (IL-9) is initially described as a growth factor secreted by helper T cells. Recently, the oncogenic activities of IL-9 were reported in some leukemia but not chronic lymphocytic leukemia (CLL). The purpose of the present study is to investigate the expression of IL-9 from patients with CLL and to evaluate its correlation with clinical characteristics. Serum and peripheral blood mononuclear cells (PBMCs) from patients with CLL were analyzed using ELISA, RT-PCR, and western blot. ELISA analysis indicated IL-9 could be detected in 20 of 47 sera from CLL patients while none serum sample from healthy volunteers contained detectable levels of IL-9. There was a higher expression of IL-9 within PBMCs from patients with CLL compared with B cells of healthy blood donors using RT-PCR and western blot. The upregulated IL-9 was correlated to the clinical staging, ZAP-70 expression, β2 microglobulin expression and IgVH status of CLL patients (P<0.05). Our findings suggest that overexpression of IL-9 may contribute to the pathogenesis of CLL and is associated with some adverse prognostic parameters.
Indexed as
Identifiers
24551294PMC3925918W267487627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.